Role of Citicoline in Patients With Mild Cognitive Impairment
Neuroscience Insights · 2023-01 · 18
DOI: 10.1177/26331055231152496 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuroscience Insights, online erschienen am 16.02.2023. Verfasst von Pedro E Bermejo und 2 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Puerta de Hierro-Majadahonda, Madrid, Spain. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The term mild cognitive impairment (MCI) defines an intermediate state between normal aging and dementia. Vascular cognitive impairment refers to a decline in cognitive function that is caused by or associated with vascular disease and comprises all the spectrum of cognitive impairments, from MCI of vascular origin to vascular dementia. One of the available treatments for cognitive impairment is cytidine diphosphate-choline (CDP-Choline), or citicoline. The objective of the present manuscript is to provide complete evidence about the efficacy of citicoline for MCI, especially of vascular origin, but also due to other neurodegenerative disorders. Citicoline is a pharmaceutical product constituted by the combination of 2 natural molecules (cytidine and choline) and is marketed as a food supplement. It has been proposed to provide neuroprotective effects through diverse mechanisms of action. Taking into account the available literature, citicoline has shown a consistent improvement in cognitive function in patients with MCI, especially of vascular origin. Moreover, it provides beneficial effects on vascular, Alzheimer, and mixed dementias, stroke sequelae, intracerebral hemorrhages, traumatic brain injuries, and neurodegenerative diseases. Long-term treatment with citicoline has also been demonstrated to be well-tolerated and has not been associated with severe adverse events. Citicoline is a safe, well-tolerated, and promising agent with evidenced neuroprotective properties.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Hospital Puerta de Hierro-Majadahonda, Madrid, Spain.
- Instituto Neurológico Beremia, Madrid, Spain.
- Alzheimer's Centre Reina Sofia-CIEN Foundation, Madrid, Spain.
ORCID-Profile: Pedro E Bermejo
Zitieren
APA
Bermejo, P. E., Dorado, R., & Zea-Sevilla, M. A. (2023). Role of Citicoline in Patients With Mild Cognitive Impairment. Neuroscience Insights, 18. https://doi.org/10.1177/26331055231152496
Vancouver
Bermejo PE, Dorado R, Zea-Sevilla MA. Role of Citicoline in Patients With Mild Cognitive Impairment. Neuroscience Insights. 2023;18. doi:10.1177/26331055231152496
BibTeX
@article{Bermejo2023,
author = {Bermejo, Pedro E and Dorado, Rodolfo and Zea-Sevilla, María Ascensión},
title = {Role of Citicoline in Patients With Mild Cognitive Impairment},
journal = {Neuroscience Insights},
year = {2023},
volume = {18},
doi = {10.1177/26331055231152496}
}
EUVIMED